Other languages ContraFect Corporation

Equities

CFRXQ

US2123264093

Market Closed - OTC Markets Other stock markets 12:27:08 2024-05-10 pm EDT			5-day change	1st Jan Change
0.014 ^USD	+19.66%		-12.50%	-53.33%

May. 03	North American Morning Briefing : Apple, Amgen -2-	DJ
Apr. 26	North American Morning Briefing : Tech Still in -2-	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ContraFect Corporation Announces Management Resignations	Dec. 05
ContraFect Corporation Announces Resignation of Michael Messinger as Chief Executive Officer	Dec. 05
ContraFect Corporation Filed for Bankruptcy	Dec. 04
ContraFect Corporation Announces Chief Executive Officer Changes	Nov. 15
ContraFect Corporation Announces Executive Changes	Nov. 15
ContraFect Corporation Implements Restructuring Plan Resulting in Reduction to Workforce from A Total of 23 Employees to Five Employee	Nov. 15
ContraFect Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
ContraFect Submits Investigational New Drug Application for Bacterial Pneumonia Treatment	23-09-18
ContraFect Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
ContraFect Corporation Presents Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company's Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-Neg Pathogens	23-06-20
Top Premarket Gainers	23-06-09
ContraFect Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
CONTRAFECT CORPORATION SHARES UP 19.9% AFTER Q1 LOSS NARROWS…	23-05-15
Top Midday Gainers	23-04-27
US Equities Shed Earlier Gains Pre-Bell as Lower-Than-Expected Q1 GDP Growth Sparks Economic Slowdown Concerns	23-04-27
Top Premarket Gainers	23-04-27
Contrafect Corporation Announces First Patient Dosed in the Phase 1B/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee	23-04-26
ContraFect Corporation Announces Data Presentations at 33rd Annual ECCMID Meeting Highlight Potential Efficacy of Lysins CF-370 Against Antibiotic Resistant Gram-Negative Pathogens	23-04-20
Better-Than-Expected Corporate Earnings Boost Sentiment, Lifting US Equity Futures	23-04-18
Top Premarket Decliners	23-04-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ContraFect Corporation

Equities

CFRXQ

US2123264093

Other languages

Filters